Abstract: An energy exchange system includes a plurality of service ports, each receptive to a connectivity device. The connectivity device physically connects a vehicle to the energy exchange system for exchanging energy services. Each vehicle using the energy exchange system is known to the system. Consequently, a vehicle may be secured to the service port to prevent theft in the case of home or parking lot service ports and to retain vehicles reported stolen in the case of other service locations, such as fast-fill stations. Associated with the energy exchange process is a clamping of the connectivity device. Disabling of the clamp release in response to a vehicle stolen or unauthorized use status, prevents the vehicle from being removed from the service port. Additional measures such as disabling the vehicle drive train or fuel system may be used to further ensure that the vehicle is retained.

Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: 1

Abstract: The present invention relates to prodrugs of a class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of prodrugs of HIV aspartyl protease inhibitors characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient. This invention also relates to pharmaceutical compositions comprising these prodrugs. The prodrugs and pharmaceutical compositions of this invention are particularly well suited for decreasing the pill burden and increasing patient compliance. This invention also relates to methods of treating mammals with these prodrugs and pharmaceutical compositions.

Abstract: The present invention relates to a novel class of sulfonamides of formula I which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity. The sulfonamides of formula I have the structure: wherein A, B, D, D′, E, G and R7 are as defined above.

Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: 1

Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: 1

Abstract: This invention relates to a connectivity device for passively connecting a vehicle to a service port. The connectivity device comprises a mount for mounting to one of the vehicle or service port; a deployment apparatus movably attached to the mount; a plug for coupling to a receptacle in the other of the vehicle or service port; and, a compliant member attaching the plug to the deployment apparatus. The compliant member provides sufficient compliance for the plug to engage the receptacle when the connectivity device is in range of but not perfectly aligned with the receptacle.

Abstract: The present invention relates to prodrugs of a class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of prodrugs of HIV aspartyl protease inhibitors characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient. This invention also relates to pharmaceutical compositions comprising these prodrugs. The prodrugs and pharmaceutical compositions of this invention are particularly well suited for decreasing the pill burden and increasing patient compliance. This invention also relates to methods of treating mammals with these prodrugs and pharmaceutical compositions.

Abstract: The present invention relates to prodrugs of a class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of prodrugs of HIV aspartyl protease inhibitors characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient. This invention also relates to pharmaceutical compositions comprising these prodrugs. The prodrugs and pharmaceutical compositions of this invention are particularly well suited for decreasing the pill burden and increasing patient compliance. This invention also relates to methods of treating mammals with these prodrugs and pharmaceutical compositions.

Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

Abstract: A class of compounds are disclosed of the formula: ##STR1## wherein R represents an alkylene or alkylidene radical having from 2 to 10 carbon atoms, which compounds are effective inhibitors for oxidation prone hydrocarbon materials in general and represent singularly effective stabilizersfor rubber, both natural and synthetic, as well as certain plastic compositions containing a rubbery phase. An improved process for preparing the aforesaid compounds and certain homologs thereof likewise representing useful oxidation inhibitors is additionally disclosed.